Zoetis Inc. ZTS
71.05
0.78
1.11%
as of 25 Sep
- Market cap
- $29.2B
- P/E
- 11.7×
Follow ZTS
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Zoetis Inc. (ZTS) Free cash flow margin
Zoetis Inc.'s free cash flow margin over the twelve months to 30 June 2026 was 24.4%, up 0.3 percentage points from fiscal 2025 (24.1%). Over the past ten years it has ranged from 9.28% (fiscal 2015) to 25.9% (fiscal 2018); the current reading is higher than 73% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 0.00% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Annual
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 24.1% | (0.71) |
| FY2024 | 24.8% | 5.86 |
| FY2023 | 19.0% | 2.55 |
| FY2022 | 16.4% | (5.93) |
| FY2021 | 22.4% | (3.03) |
| FY2020 | 25.4% | 3.72 |
| FY2019 | 21.7% | (4.23) |
| FY2018 | 25.9% | 4.05 |
| FY2017 | 21.8% | 9.83 |
| FY2016 | 12.0% | 2.73 |
Against its own ten years
Low 9.28%
High 25.9%
Ten-year median
21.8%
Current reading's percentile
73
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| UTHR United Therapeutics Corporation compare | 34.7% |
| NBIX Neurocrine Biosciences, Inc. compare | 25.8% |
| TAK Takeda Pharmaceutical Co. compare | 24.7% |
| ZTS Zoetis Inc. | 24.4% |
| VTRS Viatris Inc. compare | 12.8% |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 8.09% |
| ELAN Elanco Animal Health Incorporated compare | 7.55% |
| RDY Dr. Reddy's Laboratories Ltd compare | 4.05% |
| HLN Haleon PLC Sponsored ADR compare | 0.00% |
| Drug Manufacturers Specialty & Generic industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on ZTS
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement